Where do you see growth opportunities for Sigma-Aldrich in the life sciences market?

Mr Sachdev: In life sciences, we see opportunities in both products and services. Let's first talk about services. Recently, we acquired BioReliance, a leading provider of global biopharmaceutical testing services, on the basis that life sciences and biopharma will continue to grow in the coming years. On the product side, we have been making a lot of investments in biomolecules and antibodies. We are offering over 50,000 antibodies. We are also licensing platform technologies and have have exclusive worldwide rights for them to be used for research purposes to create cell lines and animal models. We are also licensing other technologies, such as iPS technology from Kyoto University for stem cell research.